RGS's deal is superior.
About USD16.5 million better.
OCC's recent dilutive cr at $0.40 for $4 million now makes sense. Initially I thought it was a cushion buying time so as to not be pressured into a predatory deal. Now it seems the money will fund its part of the "research collaboration."
World class outfit, scant details, apparently no money for OCC.
Regarding RGS, volume has been disappointing. Will the imminent conference be the catalyst for RGS to reach the next level? Stem cell research is the right space, eg. demographics.
OV
Ann: Regeneus and AGC collaborate on Progenza in Japan, page-102
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
